The Design of New HIV-IN Tethered Bifunctional Inhibitors Using Multiple Microdomain Targeted Docking

Abstract

Currently, used antiretroviral HIV therapy drugs exclusively target critical groups in the enzymes essential for the viral life cycle. Increased mutagenesis of their genes changes these viral enzymes, which once mutated can evade therapeutic targeting, effects which confer drug resistance. To circumvent this, our review addresses a strategy to design and derive HIV-Integrase (HIV-IN) inhibitors which simultaneously target two IN functional domains, rendering it inactive even if the enzyme accumulates many mutations. First we review the enzymatic role of IN to insert the copied viral DNA into a chromosome of the host T lymphocyte, highlighting its main functional and structural features to be subjected to inhibitory action. From a functional and structural perspective we present all classes of HIV-IN inhibitors with their most representative candidates. For each chosen compound we also explain its mechanism of IN inhibition. We use the recently resolved cryo EM IN tetramer intasome DNA complex onto which we dock various reference IN inhibitory chemical scaffolds such as to target adjacent functional IN domains. Pairing compounds with complementary activity, which dock in the vicinity of a IN structural microdomain, we design bifunctional new drugs which may not only be more resilient to IN mutations but also may be more potent inhibitors than their original counterparts. In the end of our review we propose synthesis pathways to link such paired compounds with enhanced synergistic IN inhibitory effects.

Bifunctional Inhibitors of Influenza Virus Neuraminidase: Molecular Design of a Sulfonamide Linker

“…A possible solution would be to create bifunctional compounds that occupy the sialic acid binding cavity and the adjacent 430-cavity ( Figure 2 ). It is assumed that, when using bifunctional inhibitors, mutations in one of the binding sites may be less critical if effective interactions with another site are maintained, which, in turn, can hinder the selection of resistant mutant strains of the virus [ 17 , 18 ]. This approach allows the creation of more effective inhibitors, the use of which reduces the risk of resistance due to complex interactions with the target protein.…”

A Bifunctional Nucleoside Probe for the Inhibition of the Human Immunodeficiency Virus-Type 1 Reverse Transcriptase

“…Bifunctionality is desirable as it increases the potency and binding strength of an inhibitor or drug for its target through the introduction of additional moieties that target the enzyme. − Inspired by bifunctional strategies employed in PROTACS, ligand-directed covalent modifiers, and others, − we constructed a bifunctional probe using a simple click reaction for the in vitro conjugation of the alkyne group of 3 to the azide group of AzTTP (Scheme ). Following the click reaction, excess copper was removed using stripped Ni-NTA resin.…”